Bereich

Gynäkologie & Gynäkologische Onkologie

Ansprechpartner

Ambulanz

Rufnummer

Tel.: +49 (0) 201 174-34444

Fax: +49 (0) 201 174-34000

Publikationen 2011 bis 2017

  • 2011
  • 1. von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching P, Eiermann W, Blohmer J-U, Costas SD, Mehta K, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jüni P
  • Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials, Breast Cancer Res Treat, 125: 145-156, 2011
  • https://www.ncbi.nlm.nih.gov/pubmed/?term=21042932
  • 2. Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A
  • Prospective validation study of a predictive score for operability of recurrent ovarian cancer: The multicenter Intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.Int J Gynecol Cancer, 21(2): 419-423, 2011
  • https://www.ncbi.nlm.nih.gov/pubmed/?term=21270612
  • 3. Rustin G J S, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Fried-lander M, Cervantes A, Vermorken J Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).Int J Gynecol Cancer 21: 419-423, 2011
  • https://www.ncbi.nlm.nih.gov/pubmed/?term=21270624
  • 4. Pfisterer J, Harter P, Simonelli C, Peters M, Berek J, Sabbatini P, du Bois A, Abagovomab for ovarian cancer, Expert Opin Biol Ther 11: 395-403, 2011
  • https://www.ncbi.nlm.nih.gov/pubmed/?term=21241213
  • 5. Harter P, Muallem Z, Buhrmann C, Lorenz D, Kaub C, Hils R, Kommoss S, Heitz F, Traut A, du Bois A. Impact of a stuctures quality managment program on surgical outcome in primary advanced ovarian cancer, Gynecol Oncol, 2011
  • 6. Thigpen T, du Bois A, McAlpine J, DiSaia P, Fujuwara K, Hoskins W, Kristensen G, Mannel R, Markmann M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda An, Rubinstein L, Bacon M, Kitchener H, Stuart G, on behalf of the Gynecologic Cancer InterGroup
  • First-Line Therapy in Ovarian Cancer trials, J Gynecol Cancer, 21; 756-762, 20 11
  • 7. https://www.ncbi.nlm.nih.gov/pubmed/21543937
  • 8. Stuart G, Kitchener H, Bacon M, du Bois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble, on behalf of the participants of the 4th Ovarian Cancer Consensus Conference (OCCC), 2010 Gynecologic CancerInterGroup (GCIG), Consensus statement on clinical trials in ovarian cancer, Report from the fourth Ovarian Cancer Conensus Conference., J Gynecol Cancer, 21: 750-755, 2011
  • 9. Sehouli J, Wagner U, Pölcher M, du Bois A für die Kommission Ovar der AGO und die beiden kooperativen Studiengruppen in Deutschland, AGO-Studiengruppe und NOGGO, Neoadjuvante Chemotherapie kann nicht als Standardtherapie beim Ovarialkarzinom angesehen werden, Frauenarzt 52(1): 2-5, 2011
  • 10. von Minckwitz, Müller BM, Loibl, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss, E, Huober J, Blohmer JU, du Bois A, Zahm DM, Khandran F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, Denkert C,
  • Cytoplasmic poly (adenosine disphoshate-ribose) polymerase expression is predictive and prognostic in patientes with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol, 29: 2150-2157, 2011
  • https://www.ncbi.nlm.nih.gov/pubmed/?term=21519019
  • 11. Bergmann TK, Gréen H, Brasch-Andersen C, Mirza M, Herrstedt J, Holund B, du Bois A, Damkier P, Vach W, Brosen K, Peterson C, Retrospective study oft the impact of pharmacogentic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 67: 693-700, 2011
  • 12. Heitz F, du Bois A, Kurzeder C, Pfisterer J, Barinoff J, Grabowski J, Hilpert F, Harter P, Surgery for recurrent ovarian cancer. Woman’s Health, 7(5): 529-35- 2011
  • 13. du Bois A, Marth C, Pfisterer J, Harter P, Hilpert F, Zeimet AG, Sehouli J,
  • Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer. Int J Gynecol Cancer, 21: 1165-1168, 2011 https://www.ncbi.nlm.nih.gov/pubmed/?term=22274314
  • 14. Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S. Pathologic complete response after neoadjuvant Chemotherapy plus Trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-Ovar-expressing breast cancer: results from the TECHNO trial of the AGO an GBG study groups. J Clin Oncol, 29(25): 3351-7, 2011
  • https://www.ncbi.nlm.nih.gov/pubmed/?term=21788566
  • 15. Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Tropé CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, Braicu EI, Rabbitt CA, Oksefjell H, Tian WJ, Fotopoulou C, Pfisterer J, du Bois A, Berek JS. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer, 105: 890-6, 2011 https://www.ncbi.nlm.nih.gov/pubmed/?term=21878937
  • 16. Rochon J, du Bois A, Clinical resaearch in epithelial ovarian Cancer and patients outcome. Annals of Oncology 22 (suppl 7): vii16-vii19, 2011
  • 17. Heitz F, Rochon J, Harter P, Lück H-J, Fisseler-Eckhoff A, Barinoff J, Traut A. Lorenz-Salehi F, du Bois A, Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival, Ann Oncol 22: 1571-1581, 2011 https://www.ncbi.nlm.nih.gov/pubmed/?term=21059640
  • 18. Greimel E, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, Pujade-Lauraine E, du Bois A, Toxicity and quality of life outcomes in ovarian cancer patients partici-pating in randomized controlled trials, Support Care Cancer 19: 1421-1427, 2011 https://www.ncbi.nlm.nih.gov/pubmed/?term=20694564
  • 19. von Minckwitz G, Loibl S, Jackisch C, Paepke S, Nestle-Kraemling C, Lux MP, Maass N, Schmutzler R, du Bois A, Wallwiener D, Vescia S, Budischewski K, Kaufmann M, The GISS Trial: A phase-II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer, Cancer Epidemiol Biomarkers Prev; 20(10): 2141-9, 2011 https://www.ncbi.nlm.nih.gov/pubmed/?term=21795500
  • 20. Baumann KH, Pfisterer J, Wimberger P, Burchardi N, Kurzeder C, du Bois A, Loibl S, Sehouli J, Huober J, Schmalfeldt B, Intraperitoneally treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group, 2011. Gynecol Oncol, 123: 27-32, 2011
  • 21. Loibl S, Müller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B, Kulmer U, Alles JU, Mehta K, Denkert C.
  • Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treted with neoadjuvante chemotherapy. Breast Cancer Res Treat, 130(2): 477-87, 2011
  • 22. Marth C, Zeimet A, du Bois A. Is neoadjuvant chemotherapy in ovarian cancer an excuse for insufficient surgery?, Oncology, 25: 940- 944, 2011 https://www.ncbi.nlm.nih.gov/pubmed/?term=22010393
  • 23. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. A phase III trial of bevaci-zumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96. https://www.ncbi.nlm.nih.gov/pubmed/?term=22204725
  • 24. Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G.
  • Topotecan weekly versus conventional five-day schedule in patients with platinum-resistant ovarian cancer (TOWER). A randomized multi-center trial of the NOGGO Ovarian Cancer Study Group. J Clin Oncol 2011; 29: 242-248 https://www.ncbi.nlm.nih.gov/pubmed/?term=21115872
  • 25. Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade- Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GCE on behalf of the Gynecologic Cancer InterGroup. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 2011;21:771-775 https://www.ncbi.nlm.nih.gov/pubmed/?term=21543939
  • 26. Witzel I, Loibl S, von Minckwitz G, Mundhenke C, Huober J, Hanusch C, Henschen S, Hauschild M, Lantzsch T, Tesch H, Latos K, Just M, Hilfrich J, Barinoff J, Eulenburg CZ, Roller M, Untch M, Müller V. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res Treat. 2010 Sep;123(2):437-45. Epub 2010
  • 27. https://www.ncbi.nlm.nih.gov/pubmed/?term=20623180
  • 28. Landt S, Heidecke H, Korlach S, Reuter C, Schwidde I, Barinoff J, Thill M, Sehouli J, Kümmel S. In vitro vascular tube formation testing as a tool for treatment individuallisation in patients with cervical cancer.Anticancer Res. 2011 Aug;31(8):2609-15. https://www.ncbi.nlm.nih.gov/pubmed/?term=21778312
  • 29. Landt S, Heidecke H, Reuter C, Korlach S, Blohmer JU, Lichtenegger W, Heusner T, Stöblen F, Thill M, Barinoff J, Sehouli J, Kümmel S. The utility of an in vitro angiogenesis score for prognosis assessment in patients with cervical cancer. Anticancer Res. 2011 Aug;31(8):2645-9. https://www.ncbi.nlm.nih.gov/pubmed/?term=21778317
  • 30. Landt S, Mordelt K, Schwidde I, Barinoff J, Korlach S, Stöblen F, Lichtenegger W, Sehouli J, Kümmel S. Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer. Anticancer Res. 2011 Aug;31(8):2651-5. https://www.ncbi.nlm.nih.gov/pubmed/?term=21778318
  • 31. von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S; Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG
  • 3-05 phase III study in HER2-positive breast cancer. GBG 26/BIG 03-05 study group and participating investigators. Eur J Cancer. 2011 Oct;47(15):2273-81. Epub 2011 https://www.ncbi.nlm.nih.gov/pubmed/?term=21741829
  • 32. Epstein E, Van Holsbeke C, Mascilini F, Måsbäck A, Kannisto P, Ameye L, Fischerova D, Zannoni G, Vellone V, Timmerman D, Testa AC.
  • Gray-scale and color Doppler ultrasound characteristics of endometrial cancer in relation to stage, grade and tumor size. Ultrasound Obstet Gynecol. 2011 Nov;38(5):586-93. https://www.ncbi.nlm.nih.gov/pubmed/?term=21547974
  • 33. Sauer, G., Kurzeder, C. Wann ist eine pelvine und paraaortale Lymphonodektomie bei Vorliegen eines fortgeschrittenen Ovarialkarzinoms sinnvoll? Analyse dreier prospektiv randomisierter Phase-Ill-Multicenterstudien. Strahlentherapie und Onkologie, 2011 Mar, 187(3), 215.
  • 34. Scholl SM, Kenter G, Kurzeder C, Beuzeboc P.
  • Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective. SRN Oncol. 2011;2011:403098. Epub 2011 https://www.ncbi.nlm.nih.gov/pubmed/?term=22091418
  • 35. Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Beckmann MW, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Nekljudova V, Lebeau A, Loibl S, Fasching PA; on behalf of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) PREPARE (Preoperative Epirubicin, Paclitaxel, Darbepoetin) investigators. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis. Ann Oncol. 2011 Mar 17. https://www.ncbi.nlm.nih.gov/pubmed/?term=21385882
  • 36. Regierer AC, Wolters R, Kurzeder C, Wöckel A, Novopashenny I, Possinger K, Wischnewsky MB, Kreienberg R. High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS? Breast Cancer Res Treat. 2011 https://www.ncbi.nlm.nih.gov/pubmed/?term=21210206
  • 37. Schwentner L, Kurzeder C, Kreienberg R, Wöckel .A. Focus on haematogenous dissemination of the malignant cystosarcoma phylloides: institutional experience. Arch Gynecol Obstet. 2010 Nov 11. Onkologie, 2011 Mar, 187(3), 2015, https://www.ncbi.nlm.nih.gov/pubmed/?term=21069366
  • 38. Gultekin M, Dursun P, Vranes B, Laky R, Bossart M, Grabowski JP et al. Gynecologic oncology training systems in Europe: a report from the Euro-pean Network of Young Gynaecological Oncologists. Int J Gynecol Cancer. 2011 Nov;21(8):1500-6. https://www.ncbi.nlm.nih.gov/pubmed/?term=21720256
  • 39. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minck-witz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. (As Collaborator: du Bois A )
  • Adjuvant trastuzumab in Her2-positive breast cancer. N Engl J Med.;365: 1273-83, 2011
  • 40. Heitz F, du Bois A,PARP inhibition: opening up new horizons? Clin. Invest. 1 (6): 759-762, 2011
  • Publikationen in 2011: 39
  • 2012
  • 41. Grabowski J P, Harter P, Buhrmann C, Lorenz D, Hils R, Kommoss S, Traut A, du Bois A, Re-operation outcome in patients referred to a gynaecologic oncology center with presumed ovarian cancer FIGO I-IIIA after sub-standard initial surgery. Surg Oncol 21: 31-35, 2012 https://www.ncbi.nlm.nih.gov/pubmed/?term=20875732
  • 42. du Bois A, Bevacizumab – Die Anti-Angiogenese in der Primärtherapie beim fortgeschritte-nen Ovarialkarzinom, Thieme Drug Report 2012. Geburtsh Frauenheilkd 6: 1-12, 2012
  • 43. Tian WJ, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, Cormio G, Xing Y, Breitbach GP, Braicu EI, Rabbitt CA, Oksefjell H, Fotopoulou C, Meerpohl HG, du Bois A, Berek JS, Zang RY, Harter P, A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection, Ann Surg Oncol 19(2): 597-604, 2012, https://www.ncbi.nlm.nih.gov/pubmed/?term=21732142
  • 44. Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Ottevanger N, Del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, Van der Zee A.G.J, du Bois A, The European Network of Gynaecological Oncological Trial groups. Clin Invest, 2: 35-7, 2012
  • 45. du Bois A, Marth C, Pfisterer J, Harter P, Hilpert F, Zeimet AG, Sehouli J. Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer. Int J Gynecol Cancer, 22: 182-5, 2012, https://www.ncbi.nlm.nih.gov/pubmed/?term=22274314
  • 46. du Bois A, Vergote I, Wimberger P, Ray-Coquard I, Harter P, Stutts M, Baylor Curtis L, Mitrica I, Open-Label Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women with Newly Diagnosed, Untreated, Gynecologic Tumors: A Phase I/II Trial of the AGO Study Group; Br J Cancer 106: 629-32, 2012, https://www.ncbi.nlm.nih.gov/pubmed/?term=22240783
  • 47. Baumann KH, du Bois A, Meier W, Rau J, Wimberger P, Sehouli, J, Kurzeder C, Hilpert F, Hasenburg A, Canzler U, Hanker LC, Hillemanns P, Richter B, Wollschlaeger K, Dewitz T, Bauerschlag D, Wagner U, A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol, 23: 2265-2271, 2012, https://www.ncbi.nlm.nih.gov/pubmed/?term=22377563
  • 48. Hilpert F, Wimberger P, du Bois A, Pfisterer J, Harter P,
  • Treatment of elderly ovarian cancer patients in the context of controlled clinical trials – a joint analysis of the AGO Germany expierience. Oncology, 35: 76-81, 2012, https://www.ncbi.nlm.nih.gov/pubmed/?term=22414969
  • 49. Heitz F, du Bois A, Rochon J, Scheil-B S, Hils R, Fisseler-E A, Barinoff J, Kaub C, Harter P, Requirements to Assess Feasibility of Phase 0 Trials during Major Abdominal Surgery - Variability of Poly (ADP-Ribose) Polymerase Activity, Clin Cancer Res, 18: 2632-7, 2012
  • 50. Ewald-Riegler N, du Bois O, Fisseler-Eckhoff A, Kommoss F, Harter P, Traut A,, du Bois A, Borderline tumors of the ovary: clinical course and prognostic factors. Onkologie, 35: 28-33, 2012 https://www.ncbi.nlm.nih.gov/pubmed/?term=22310342
  • 51. Meier W, du Bois A, Rau J, Gropp-Meier M, Baumann K, Huober J, Woll-schlaeger K, Kreienberg R, Canzler U, Schmalfeldt B, Wimberger P, Richter B, Schröder W, Belau A,Stähle A,, Sehouli J, Randomized Phase II Trial of Carboplatin and Paclitaxel with or without Lonafarnib in First-Line Treatment of Epithelial Ovarian Cancer Stage IIB-IV. Gynecol Oncol, 126: 236-40, 2012
  • 52. Sehouli J, Runnebaum IB, Fotopoulou C, Blohmer U, Belau A, Leber H, Hanker LC, Hartmann W, Richter R, Keyver-Paik MD, Oberhoff C, Heinrich G, du Bois A, Olbrich C, Simon E, Friese K, Kimmig R, Boehmer D, Lichtenegger W, Kuemmel S.
  • A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation: a NOGGO-AGO Intergroup Study. Ann Oncol, 23: 2259-2264, 2012 https://www.ncbi.nlm.nih.gov/pubmed/?term=22357252
  • 53. Schippert C, Warm M, Blohmer JU, du Bois, A, Lück HJ,
  • Mitomycin C in combination with vinorelbine in anthacycline and/or taxane-prectreated patients with metastatic breast cancer. Onkologie, 35, 500-504, 2012
  • 54. Muallem MZ, Harter P, Heitz F, El-Balat A, Fisseler-Eckhoff A, Menzel C,
  • du Bois A, Struma ovarii recurrence with peritoneal strumosis: A case report, J Solid Tumors 2(6): 46-50, 2012
  • 55. Harter P, Heitz F, du Bois A,
  • Surgery for relapsed Ovarian Cancer: When should it be offered? Curr Oncol Rep, 14:539-43, 2012, https://www.ncbi.nlm.nih.gov/pubmed/?term=22918696
  • 56. Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, Ray-Coquard I, Sehouli J, Harter P, du Bois A on behalf of the AGO and GINECO study group,
  • The impact of 2nd to 6th line therapy on survival of relapsed ovarian cancer after primary taxane/ platinum based therapy. Ann Oncol 23: 2605-2612, 2012
  • Publikationen in 2012: 16
  • 2013
  • 57. Mahner S, Eulenburg C, Staehle A, Wegscheider K, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J, du Bois A, Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials, Eur J Cancer, 49, 142-149, 2013, https://www.ncbi.nlm.nih.gov/pubmed/?term=22921185
  • 58. Barinoff J, Hils R, Bender A, Groß J, Kurz C, Tauchert S, Mann E, Schwidde I, Ipsen B, Sawatzki K, Heitz F, Harter P, Traut A, du Bois A,
  • Clinicopathologic differences between breast cancer in patients with primary metastatic disease and those without: a multicentre study.Eur J Cancer, 49, 305-311, 2013
  • 59. Harter P, Mahner S. Hilpert F, Runnebaum I, Ortmann O, Mustea A, Sehouli J, du Bois A, Wagner U for the Kommission Ovar of the Arbeitsgemeinschaft Gynäkologische Onkologie, Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.Geburtsh Frauenheilk, 73, 221-223, 2013, https://www.ncbi.nlm.nih.gov/pubmed/?term=24771913
  • 60. du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S
  • Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer, 49, 1905-1914, 2013, https://www.ncbi.nlm.nih.gov/pubmed/?term=23490647
  • 61. Pharoah P, Tsai YY, Ramus S, Phelan C, Goode E, du Bois A, et al
  • GWAS meta-analysis and replication identifies three novel common suspectibility for ovarian cancer. Nat Genet. 45, 362-370, 370e1-2, 2013, https://www.ncbi.nlm.nih.gov/pubmed/?term=23535730
  • 62. Bojesen S, Poole K, Johnatty S, du Bois A et al,
  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 45, 371-384, 2013
  • 63. White K, Vierkant R, Fogarty Z, .., du Bois A et al,
  • Analysis of over 10,000 cases finds no association between previously-reported candidate polymer-phisms and ovarian cancer outcome. Cancer Epidemiol Biomarkers Prev, 22: 987-92, 2013 , https://www.ncbi.nlm.nih.gov/pubmed/?term=23513043
  • 64. Heitz F, du Bois A, Harter P, Lubbe D, Kurzeder C, Vergote I, Plante M, Pfisterer J; on behalf of the AGO, NCIC-CTG and EORTC-GCG study groups
  • Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol, 129: 463-6, .2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=23500609
  • 65. Bauerschlag D, Hilpert F, Meier W, Rau J, Meinhold-Heerlein I, Maas N, du Bois A, Sehouli J, Arnold N, Schem C, Oberg HH, Baumann K,
  • Evaluation of potentially predictive markers for anti-angionenic therapy with Sunitinib in recurrent ovarian cancer. Transl Oncol. 6(3): 305–310, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=23730410
  • 66. Heitz F, Barinoff J, du Bois O, Hils R, Fisseler-Eckhoff A, Harter P, Heitz J, Willenbrock K, Traut A, du Bois A,
  • Differences in the Receptor Status between Primary and Recurrent Breast Cancer - The Frequency of and the Reasons for Discordance. Oncology, 84(6): 319-325, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=23615456
  • 67. Harter P, Heitz F, du Bois A,
  • In Reply: Response to Sammartino et al. Curr Oncol Rep, 15: 192 (letter), 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=23446871
  • 68. Lück HJ, du Bois A, Loibl S, Schrader I, Huober J, et al.,
  • Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treat-ment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group, Breast Cancer Res Treat, 139: 779-87, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=23771714
  • 69. du Bois A, Heitz F, Harter P, Fertility-Sparing surgery in ovarian cancer: a systematic Review. Onkologie, 36: 436-443, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=23921764
  • 70. Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.
  • Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial. J Natl Cancer Inst, 105: 1018-1026, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=23860204
  • 71. Vergote I, Elser G, Votan B, Farrelly L, De Roover J, Bryce J, du Bois A; member trial groups of the European Network of Gynaecological Trial groups (ENGOT),
  • Roadmap for the European Network of Gynaecological Trial Groups (ENGOT) Trials. Int J Gynecol Cancer, 23:1339-43, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=23970159
  • 72. Johnatty SE, Beesley J, Gao B, Chen X, Lu Y, …, du Bois A et al,
  • ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol. 131: 8-14, 2013. https://www.ncbi.nlm.nih.gov/pubmed/?term=23917080
  • 73. Kommoss S, Pfisterer J, Reuss A, Diebold J, Hauptmann S, Schmidt C, du Bois A, Schmidt D, Kommoss F., Specialized pathology review in patients with ovarian cancer: results from a prospective study. Int J Gynecol Cancer, 23: 1376-82, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=24257551
  • 74. Earp MA, Kelemen LE, Magliocco AM, …, du Bois A, et al,
  • Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet., 133(5): 481-97, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=24190013
  • 75. Harter P, Sehouli J, Kimmig R, Rau J, Hilpert F, Kurzeder C, Elser G, du Bois A, Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13), Invest New Drugs, 31: 1499-1504, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=24005613
  • 76. Raja FA, Counsell N, Colombo N, Pfisterer J, du Bois A, Parmar MK, Vergote IB, Gonzalez-Martin A, Alberts DS, Plante M, Torri V, Ledermann JA, Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data, Ann Oncol, 24: 3028-34, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=24190964
  • 77. Harter P, Heitz F, Mahner S, Hilpert F, du Bois A, Surgical intervention in relapsed ovarian cancer is beneficial: pro. Ann Oncol, 24 (Suppl 10): x33-x34, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=24265400
  • 78. Lück HJ, du Bois A, Loibl S, Schrader I, Huober J, Heilmann V, Beckmann M, Stähler A, Jackisch C, Hubalek M, Richter B, Stickeler E, Eidtmann H, Thomssen C, Untch M, Wollschläger K, Schuster T, von Minckwitz G, Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat, 139: 779-87, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=23771714
  • 79. Heitz F, Harter P, du Bois A, Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis. Am J Obstet Gynecol, 209: 592-3, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=23796645
  • 80. Kommoss S, Gilks CB, Kommoss F, Chow C, Hilpert F, du Bois A, Köbel M, Huntsmann DG, Anglesio M, Kalloger SE, Pfisterer J, Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput toll for case review, Histopathology, 63: 704-12, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=24033430
  • 81. Heitz F, Bender A, Barinoff J, Lorenz-Salehi F, Fisseler-Eckhoff A, Traut A, Hils R, Harter P, Kullmer U, du Bois A, Outcome of early breast cancer treated in an urban and a rural breast cancer unit in Germany. Onkologie, 36: 477-82, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=24051923
  • 82. BarinoffJ, Heitz F, Kuemmel S, Dittmer C, Hils R, Lorenz-Salehi F, Traut A, du Bois A, Improvement of Survival in Patient with Primary Metastatic Breast Cancer over a 10-Year Periode: Prospective Analyses Based on Individual Patient Data from a Multicenter Data Bank. JCT 4, 1306-1312, 2013
  • 83. Von Minckwitz G, Mübus, V, Schneeweiss A, Barinoff J…. et al., German Adjuvant Intergroup Node-positive Study: A Phase III-Trial to compare oral Ibandronate versus Observation in patients with high-risk early breast cancer,
  • J Clin Onc.,31, 3531-3539; 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=23980081
  • 84. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, …, du Bois A et al.
  • Identification and molecular characterization of a novel ovarian cancer susceptibility locus at 17q21.31. Nature commun, 4:1627, 2013
  • 85. Shen H, Fridley BL, Song H, …, du Bois A, et al,
  • Epigenetic analysis leads to identifiacation of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature commun, 4:1628, 2013
  • 86. Harter P, Schrof I, Karl LM,, Hils R, Kullmann V, Traut A, Scheller H, du Bois A
  • Sexuelle Funktion, sexuelle Aktivität und Lebensqualität bei Frauen mit Ovarial- und Endometriumkarzinom. Geburth Frauenheilk, 73: 428-432, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=24771922
  • 87. Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomsen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Angermund R, Untch M on behalf of the AGO Breast Study Group, Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel and cyclophosphamide, (IDD-ETC) ± epoetin alfa versus sequential standard chemotherapy in high-risk breast cancer patients: Mature epoetin alfa analysis results J Natl Cancer Inst. 17; 105: 1018-26, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=20458045
  • 88. Pfisterer J, Hilpert F, Mahner S, Harter P, du Bois A,
  • Primäre Systemtherapie des Ovarialkarzinoms. Der Gynäkologe, 46: 541-546, 2013
  • 89. Wagner U, Harter P, Hilpert F, Mahner S, Reuß A, du Bois A et al.
  • S3-Guideline on diagnostics, therapy and follow-up of malignant ovarian tumors, Geburtsh Frauenheilk, 73: 874–889, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=24771937
  • 90. Vergote I, du Bois A, Amant F, Heitz F, Leunen K, Harter P,
  • Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? Gynecol Oncol, 128: 6-11, 2013 https://www.ncbi.nlm.nih.gov/pubmed/?term=23006973
  • 91. Schneider S, Heitz F, Harter P, Beutel B, Kurzeder C, du Bois A, Die operative Therapie des primären Ovarialkarzinoms. Der Gynäkologe, 46, pp 536-540, 2013
  • 92. Lotten, D, Borgfeldt C, Forslund O, Henic E, Dillner J, Kannisto P., Vaginal self-sampling without preservative for human papillomavirus testing shows good sensitivity. J Clin Virology, 56, 2013, 52-56 https://www.ncbi.nlm.nih.gov/pubmed/?term=23017435
  • Publikationen in 2013: 35
  • 2014
  • 93. El-Khalfaoui K, du Bois A, Heitz F, Kurzeder C, Sehouli J, Harter P
  • Current and future options in the management and treatment of uterine sarcoma, Ther Adv Med Oncol, 6: 21-28, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=24381658
  • 94. Heitz F, Amant F, Fotopoulou C, Battista MJ, Wimberger P, Traut A, Fisseler-Eckhoff A, Harter P, Vandenput I, Sehouli J, Schmidt M, Kimmig R, du Bois R,
  • du Bois A, Synchronous Ovarian and Endometrial Cancer-an International Multicenter Case-Control Study. Int J Gynecol Cancer, 24: 54-60, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=24300466
  • 95. Rochon J, du Bois A, Lange T,
  • Mediation analysis of the relationship between institutional research activity and patient survival.BMC Med Res Methodol; 14: 9, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=24447677
  • 96. Charbonneau B, Block MS, Bamlet WR, … du Bois A, et al.
  • Risk of Ovarian Cancer and the NF-κB Pathway: Genetic association with IL1A and TNFSF10. Cancer Res. 74; 852-61, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=24272484
  • 97. Kelemen I, Terry K, Goodmann M, … du Bois A et al, Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Mol Nutr Food Res; 58(10): 2023-35, 2014
  • 98. Kannisto P, Harter P, Heitz F, Traut A, du Bois A, Kurzeder C
  • Implementation of robot-assisted gynecologic surgery for patients with low and high BMI in a German gynecological cancer center. Arch Gynecol Obstet, 290(1): 143-8, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=24532013
  • 99. Harter P, Beutel B, Alesina PF, Lorenz D, Boergers A, Heitz F, Hils R, Kurzeder C, Traut A, du Bois A,
  • Prognostic and predictive value of the Arbeitsgemein-schaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecol Oncol., 132: 537-41, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=24462732
  • 100. Trillsch F, Mahner S, Woelber L, Vettorazzi E, …, du Bois A,
  • Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: An analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT Study. Ann Oncol, 25: 1320-7, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=24618151
  • 101. Harter P, El Khalfaoui K, Heitz F, du Bois A, Operative und konservative Behandlung uteriner Sarkome. Geburtsh Frauenheilk; 74: 267-270, 2014
  • 102. Kommoss S, Pfisterer J, du Bois A, Schmidt D, Kommoss F,
  • Specialized histopathological second opinion of advanced ovarian Cancer: Experiences with collectives prospective randomized phase III studies. Pathologe; 35:355-360, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=24992975
  • 103. Hedditch E, Gao B, Russell A, Lu Y, Emmanuel C, …, du Bois A et al,
  • ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer, J Nat Cancer Inst, 106(7):dju 149, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=24957074
  • 104. Nitz U, Gluz O, Huober J, …..du Bois A et al. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1)) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol, 25: 1551-7, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=27634692
  • 105. Hauptmann S, du Bois A, Meinhold-Herlein I, Pfisterer J, Avril S
  • Die histologische Malignitätsgraduierung des Ovarialkarzinoms – Überblick und Empfehlung. Pathologe; 35(5): 497-503, 2014
  • 106. Charbonneau B, Moysich KB, Kalli KR, …, du Bois A, Harter P, …, Heitz F et al, Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunol Res.; 2(4): 332-40, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=24764580
  • 107. du Bois A, Floquet A, Kim JW, Rau J, Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer. J Clin Oncol, 32, 3374-82, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=25225436
  • 108. Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HK, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz UA, Runnebaum IB, Hinke A, Kreienberg R, Untch M;
  • AGO Breast Study Group: Response to letters. J Natl Cancer Inst.106(3): djt4352. 2014
  • 109. Ataseven B, Grimm C, Harter P, Prader S, Traut A, Heitz F, du Bois A,
  • Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer. Gynecol Oncol, 135: 435-40, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=25312398
  • 110. Block M, Charbonneau B, Vierkant R, … du Bois A et al
  • Variation in NF-κB Signaling Pathways and Survival of Invasive Epithelial Ovarian Cancer. Cancer Epidemiol Biomarkers Prev, 23: 1421-7, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=24740199
  • 111. Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, Mezzanzanica D, Quinn M, Maenpaa J, Kim JW, Mahner S, Hilpert F, Baumann K, Pfisterer J, du Bois A, Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Tumors of Low Malignant Potential (Borderline Ovarian Tumors). Int J Gynecol Cancer, 24 (9 Suppl 3): S 5-8. 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=25341581
  • 112. Reed NS, Pautier P, Avall-Lundqvist E, Choi CH, du Bois A, Friedlander M, Fyles A, Kichenadasse G, Provencher DM, Ray-Coquard I
  • Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Small Cell Cancers.Int J Gynecol Cancer, 24 (9 Suppl 3): S 73-7, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=25341577
  • 113. Ataseven B, Grimm C, Harter P, Prader S, Traut A, Heitz F, du Bois A,
  • Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer. Gynecol Oncol, 135; 435-40, 2014 https://www.ncbi.nlm.nih.gov/pubmed/?term=25312398
  • 114. Mahner S, Meier W, du Bois A, Brown C, Lorusso D, Dell'Anna T, Cretin J, Havsteen H, Bessette P, Zeimet AG, Vergote I, Vasey P, Pujade-Lauraine E, Gladieff L, Ferrero A
  • Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial. Eur J Cancer, doi: 10.1016/j.ejca.2014.11.017, 2014 Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/?term=25534295
  • 115. Emons G, Gorchev G, Harter P, Wimberger P, Stähle A, Hanker L, Hilpert F, Beckmann MW, Dall P, Gründker C, Sindermann H, Sehouli J.
  • Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5). Int J Gynecol Cancer. 2014; 24(2):260-5 https://www.ncbi.nlm.nih.gov/pubmed/?term=24418927
  • 116. Luyten A, Sörgel P, Clad A, Gieseking F, Maass-Poppenhusen K, Lellé RJ, Harter P, Buttmann N, Petry KU. Treatment of extramammary Paget disease of the vulva with imiquimod: A retro-spective, multicenter study by the German Colposcopy Network. J Am Acad Dermatol. 2014; 70(4):644-50 https://www.ncbi.nlm.nih.gov/pubmed/?term=24433876
  • 117. Emons G, Gorchev G, Sehouli J, Wimberger P, Stähle A, Hanker L, Hilpert F, Sindermann H, Gründker C, Harter P. Efficacy and safety of aezs-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter phase II trial of the AGO-study group (AGO GYN 5). Gynecol Oncol. 2014;133:427-432 https://www.ncbi.nlm.nih.gov/pubmed/?term=24713545
  • 118. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U.
  • Olaparib maintenance therapy in patients with platinumsensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15(8):852-61 https://www.ncbi.nlm.nih.gov/pubmed/?term=24882434
  • 119. du Bois A, Floquet A, Kim JW, Rau J, del Campo, JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of Bevacizumab in Maintenance Therapy of Ovarian Cancer. J Clin Oncol 2014; 32(30):3374-82. https://www.ncbi.nlm.nih.gov/pubmed/?term=25225436
  • 120. Gourley C, Farley J, Provencher DM, Pignata S, Mileshkin L, Harter P, Maenpaa J, Kim JW, Pujaide-Lauraine E, Glasspool RM, Ray-Coquard I, Gershenson D. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S9-S13. https://www.ncbi.nlm.nih.gov/pubmed/?term=25341587
  • 121. Pautier P, Ji Nam E, Provencher DM, Hamilton AL, Mangili G, Siddiqui NA, Westermann AM, Reed NS, Harter P, Ray-Coquard I. Gynecologic Cancer InterGroup (GCIG)
  • Consensus Review for High-Grade Undifferentiated Sarcomas of the Uterus. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S73-S77. https://www.ncbi.nlm.nih.gov/pubmed/?term=25341584
  • 122. Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S55-S60. https://www.ncbi.nlm.nih.gov/pubmed/?term=25341582
  • 123. Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, Mezzanzanica D, Quinn M, Maenpaa J, Kim JW, Mahner S, Hilpert F, Baumann K, Pfisterer J, du Bois A. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Tumors of Low Malignant Potential (Borderline Ovarian Tumors). Int J Gynecol Cancer. 2014;24(9 Suppl 3):S5-S8. https://www.ncbi.nlm.nih.gov/pubmed/?term=25341581
  • 124. Brown J, Friedlander M, Backes FJ, Harter P, O'Connor DM, de la Motte Rouge T, Lorusso D, Maenpaa J, Kim JW, Tenney ME, Seckl MJ.
  • Gynecologic Cancer Intergroup (GCIG) Consensus Review for Ovarian Germ Cell Tumors. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S48-S54. https://www.ncbi.nlm.nih.gov/pubmed/?term=25341580
  • 125. Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanzanica D, Colombo N., Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Sex Cord Stromal Tumors. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S42-S47. https://www.ncbi.nlm.nih.gov/pubmed/?term=25341579
  • 126. Sagea S, Susumu N, Viswanathan AN, Aoki D, Kurzeder C, Glasspool RM, Small W Jr. et al. Gynecologic Cancer InterGroup /GCIG) cnsensus review for uterine serous carcinoma.Int J Gynecol Cancer, 2104 Nov;24:S83-S89 https://www.ncbi.nlm.nih.gov/pubmed/?term=25341586
  • 127. Hasegawa K, ,….Kurzeder C, Gladieff L, Friedlander M., Fujuwara K et al., Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma. Int J Gynecol Cancer, 2014 Nov;24:S96-S101 https://www.ncbi.nlm.nih.gov/pubmed/?term=25341588
  • 128. Ataseven, B.; Lederer, B.; Blohmer, J. U.; Denkert, C.; Gerber, B.; Heil, J.; Kuhn, T.; Kummel, S.; Rezai, M.; Loibl, S. and von Minckwitz, G.
  • Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy, Ann Surg Oncol., 2014
  • 129. Ataseven, B.; Gunesch, A.; Eiermann, W.; Kates, R. E.; Hogel, B.; Knyazev, P.; Ullrich, A. and Harbeck, N. PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs, Onco Targets Ther, 2014 (vol. 7), pp. 1723-31. https://www.ncbi.nlm.nih.gov/pubmed/?term=25336969
  • 130. Gartner, S.; Gunesch, A.; Knyazeva, T.; Wolf, P.; Hogel, B.; Eiermann, W.; Ullrich, A.; Knyazev, P, Ataseven, B. PTK 7 Is a Transforming Gene and Prognostic Marker for Breast Cancer and Nodal Metastasis Involvement. PLoS One, 2014 (vol. 9), No. 1, p. e84472. https://www.ncbi.nlm.nih.gov/pubmed/?term=24409301
  • 131. Jackisch, C.; Muller, V.; Maintz, C.; Hell, S., Ataseven, B. Subcutaneous Administration of Monoclonal Antibodies in Oncology, Geburtshilfe Frauenheilkd, 2014 (vol. 74), No. 4, pp. 343-349. https://www.ncbi.nlm.nih.gov/pubmed/?term=25076790
  • 132. Kopp, F.; Hermawan, A.; Oak, P. S.; Ulaganathan, V. K.; Herrmann, A.; Elnikhely, N.; Thakur, C.; Xiao, Z.; Knyazev, P.; Ataseven, B.; Savai, R.; Wagner, E. and Roidl, A.
  • Sequential Salinomycin Treatment Results in Resistance Formation through Clonal Selection of Epithelial-Like Tumor Cells, Transl Oncol, 2014 (vol. 7), No. 6, pp. 702-11. https://www.ncbi.nlm.nih.gov/pubmed/?term=25500079
  • 133. Darb-Esfahani, S.; von Minckwitz, G.; Denkert, C.; Ataseven, B.; Hogel, B.; Mehta, K.; Kaltenecker, G.; Rudiger, T.; Pfitzner, B.; Kittel, K.; Fiedler, B.; Baumann, K.; Moll, R.; Dietel, M.; Eidtmann, H.; Thomssen, C. and Loibl, S. Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes,
  • BMC Cancer, 2014(vol. 14), No. 1, p. 546. https://www.ncbi.nlm.nih.gov/pubmed/?term=25070172
  • Publikationen in 2014: 41
  • 2015
  • 134. Grimm C, Harter P, Heitz F, du Bois A. The Sandwich Technique of Diaphragmatic Stripping or Full-Thickness Resection for Advanced Ovarian Cancer: How to keep it short and simple.Int J Gynecol Cancer. 25: 131-4, 2015 (IF 1.279) https://www.ncbi.nlm.nih.gov/pubmed/?term=25347091
  • 135. Ataseven B, Kümmel S, Weikel W, Heitz F, Holtschmidt J, Lorenz-Salehi F, Kümmel A, Traut A, Blohmer J, Harter P, du Bois A, Additional prognostic value of lymph node ratio over pN staging in different breast cancer subtypes based on the results of 1,656 patients, Arch Gynecol Obstet, 291:1153-66, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=25367604
  • 136. Grimm C, Harter P, Heitz F, du Bois A. The Sandwich Technique of Diaphragmatic Stripping or Full-Thickness Resection for Advanced Ovarian Cancer: How to Keep it Short and Simple.Int J Gynecol Cancer. 25: 131-4, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=25347091
  • 137. Floquet A, Vergote I, Colombo N. Fiane B, Monk B, Rheinthaller A, Calvert P, Herzog T, Meier W, Kim JW, del Campo J, Friedlander M, Pisano C, Isonishi S, Crescenzo R, Barrett C, Wang K, Mitrica I, du Bois A
  • Progression-Free Survival by Local Investigator Versus Independent Central Review: Comparative Analysis of the AGO-OVAR16 Trial. Gynecol Oncol, 136: 37–42, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=25434635
  • 138. Trillsch F, Mahner S, Vettorazzi E, Woelber L, Reuss A, Baumann K,
  • du Bois A, Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study. Br. J. Cancer, 112: 660-6, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=25562434
  • 139. Farthmann J, Hasenburg A, Weil M, Fotopoulou C, Ewald-Riegler N, du Bois O, Trillsch F, Mahner S, Strauss HG, Wimberger P, Reuss A, du Bois A
  • Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group ROBOT-Study. Support Care Cancer, 23: 117-23, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=24996831
  • 140. Lee A, Tyrer J, Doherty J, Stram D, …, du Bois A et al, Evaluating the ovarian cancer gonadtropin hypothesis: a candidate gene study, Gynecol Oncol, 136:1153-66, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=25528498
  • 141. Mahner S, Meier W, du Bois A, et al, Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial, Eur J Cancer, 51: 352-58, 2015
  • 142. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, …, du Bois A et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet, 47: 164-71, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=25581431
  • 143. Davis S, Sheppard K, Anglesio M, …, du Bois A, et al. Enhanced GAB2 expression is identified in a clinically distinct subtype of high-grade serous and endometrioid ovarian cancer, Mol Cancer Ther, 1495-1503, 2015
  • 144. Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, du Bois A, Griebel LF, Woelber L; AGO-CaRE 1 investigators. Adjuvant Therapy in Lymph Node-Positive Vulvar Cancer: The AGO-CaRE-1 Study.J Natl Cancer Inst, 107, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=25618900
  • 145. Spraggs C, Parham L, Song K, Briley L, Johnson T, Russo M, Tada H, du Bois A, Xu CF. Comparison of the effects of the BIM deletion polymorphism on treatment of solid tumors by tythe tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib. Ann Oncol, 26:1515-17, 2015
  • 146. Sehouli J, Fotopoulou C, Erol E, Richter R, Reuss A, Mahner S, Lauraine EP, Kristensen G, Herrstedt J, du Bois A, Pfisterer J,. Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients. Eur J Cancer, 51: 825-32, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=%3A+25771433
  • 147. Fotopoulou C, El-Balat A, du Bois A, Sehouli J, Harter P, Muallem MZ, Krätschell RW, Traut A, Heitz F. Systematic pelvic and paraaortic lymphadenectomy in early high-risk or advanced endometrial cancer, Arch Gynecol Obstet. 2015, Epub ahead of print https://www.ncbi.nlm.nih.gov/pubmed/?term=25990476
  • 148. Buttmann-Schweiger N, Klug S, Luyten A, Holleczek B, Heitz F, du Bois A, Kraywinkel K, Incidence patterns and temporal trends of invasive vulvar tumors in Germany 1999-2011. A population-based cancer registry analysis, PLoS ONE, 10(5):e0128073. doi: 10.1371, 2015, https://www.ncbi.nlm.nih.gov/pubmed/?term=26020540
  • 149. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, …, du Bois A et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer, Nat Genet, 47: 164-71, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=25581431
  • 150. Bachmann H, Meier W, du Bois A, Kimmig R, Kuhlmann JD, Siffert W, Sehouli J, Wollschlaeger K, Huober J, Hillemanns P, Burges A, Schmalfeldt B, Aminossadati B, Wimberger P, The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients, Br J Clin Pharmacol., 80(5), 1139-48, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=26033044
  • 151. Fotopoulou C, Sehouli J, Ewald-Riegler N, de Gregorio N, Reuss A, Richter R, Mahner S, Kommoss F, Schmalfeldt B, Fehm T, Hanker L, Wimberger P, Canzler U, Pfisterer J, Kommoss S, Hauptmann S, du Bois A; ROBOT investigators. The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study, Int J Gynecol Cancer, 25: 1248-52, 2015, https://www.ncbi.nlm.nih.gov/pubmed/?term=25978292
  • 152. Buttmann-Schweiger N, Klug S, Luyten A, Holleczek B, Heitz F, du Bois A, Kraywinkel K. Incidence Patterns and Temporal Trends of Invasive Nonmelanotic Vulvar Tumors in Germany 1999-2011. A Population-Based Cancer Registry Analysis, PLoS one, doi: 10.1371, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=26020540
  • 153. Marth C, du Bois A, Schauer C, Casado A, Vergote I, Del Campo JM, Goudopoulou A, Pujade-Lauraine E, Bruchim I, Colombo N, Pignata S, Ledermann J, Chekerov R, Raza Mirza M, Westermann A, Glasspool R, Taskiran C, Fehr M, Cibula D,
  • The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership, Int J Gynecol Cancer; 25(6): 1094-5, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=26098090
  • 154. Chornokur G, Lin HY, Tyrer J, …du Bois A, et al.
  • Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk, PLoS One, 10(6):e0128106, 2015, https://www.ncbi.nlm.nih.gov/pubmed/?term=26091520
  • 155. Ovarian Cancer Association Consortium;
  • Australian Cancer Study; Australian Ovarian Cancer Study Group, Genome-wide significant risk associations for mucinous ovarian carcinoma, Nat Genet, 47: 888-97, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=26075790
  • 156. du Bois A, Reuss A, Pujade-Lauraine E, Pignata S, Ledermann J, Casado A, Sehouli J, Mirza M, Colombo N, Marth C, Witteveen E, Del Campo J, Calvert P, Aravantinos G, Vardar MA, van der Zee AG, Korach J, Taskiran C, Fehr M, Glasspool R, Pfisterer J, Cibula D, Vergote I; member trial groups of the European Network of Gynaecological Oncological Trial Groups (ENGOT), European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners-First Update 2015, Int J Gynecol Cancer, 25: 1328-30, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=26067859
  • 157. Kelemen L, … du Bois A, Harter, P, Heitz F et al,
  • Genome-wide significant risk associations for mucinous ovarian carcinoma, Nat Gen, 47:888-897, 2015
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520768/
  • 158. Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, …du Bois, Harter P et al, Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium, Br. J. Canc, 113: 817-26, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=26151456
  • 159. Oza A, Cook A, Pfisterer J, Embleton A, Ledermann J, Pujade-Lauraine E, … du Bois A, et al., Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial, Lancet Oncol, 16(8):928-36, 2015
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648090/
  • 160. Kar S, Tyrer J, Li Q, Lawrenson K, …, du Bois A, et al. Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk, Cancer Epidemiol Biomarkers Prev;24(10):1574-84, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=26209509
  • 161. Stefanidou N, Grimm C, Spitthöver R, Grabellus F, Harter P, du Bois A. Syndrome of inappropriate ADH Secretion (SIADH) during Chemotherapy with Carboplatin/Paclitaxel for Metastatic Fallopian Tube Cancer, Emerg Med (Los Angel) 5:262, 2015
  • 162. Pfisterer J, Hilpert F, Harter P, du Bois A.
  • Therapieinnovation: Der PARP-Inhibitor Olaparib, Frauenarzt, 56 (9): 758-763, 2015
  • 163. du Bois A, Trillsch F, Mahner S, Heitz F, Harter P. Management of borderline ovarian tumors (BOT), Ann Oncol, 27, Suppl 1:i20-i22, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27141065
  • 164. Lawrenson K, Iversen ES, Tyrer J, Weber RP, …, du Bois A et al.
  • Common Variants at the CHEK2 Gene Locus and Risk of Epithelial Ovarian Cancer. Carcinogenesis, 36(11):1341-53, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=26424751
  • 165. Johnatty A, Tyrer J, Kar S, Beesley J, Lu Y, … du Bois A, et al. Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clin Cancer Res, 21(23, 5264-76, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=26152742
  • 166. Amankwah EK, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, …, du Bois A et al. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genet Epidemiol., 39(8): 689-697, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=26399219
  • 167. Kümmel A, Kümmel S, Barinoff J, Heitz F, Holtschmidt J, Weikel W, Lorenz-Salehi F, du Bois A, Harter P, Traut A, Blohmer JU, Ataseven B. Prognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer, Geburtshilfe Frauenheilkd, 75, 710-718, 2015
  • https://www.ncbi.nlm.nih.gov/pubmed/?term=26257408
  • 168. Ataseven B, du Bois A, Reinthaller A, Traut A, Heitz F, Aust S, Prader S, Polterauer S, Harter P, Grimm C. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery, Gynecol Oncol, 138: 560-5, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=26163893
  • 169. Jackisch, C.; Muller, V.; Dall, P.; Neumeister, R.; Park-Simon, T. W.; Ruf-Dordelmann, A.; Seiler, S.; Tesch, H., Ataseven, B.
  • 170. Lindner, J. L.; Loibl, S.; Denkert, C.; Ataseven, B.; Fasching, P. A.; Pfitzner, B. M.; Gerber, B.; Gade, S.; Darb-Esfahani, S.; Sinn, B. V.; Huober, J.; Engels, K.; Tesch, H.; Karn, T.; Pommerenke, F.; Liedtke, C.; Untch, M.; Muller, V.; Rack, B.; Schem, C. and von Minckwitz, G.
  • Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. Ann Oncol (vol. 26), No. 1, pp. 95-100
  • https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdu487
  • 171. Lee CK, Lord S, Grunewald T, Gebski V, Hardy-Bessard AC, Sehouli J, Woie K, Heywood M, Schauer C, Vergote I, Scambia G, Ferrero A, Harter P, Pujade-Lauraine E, Friedlander M. Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. Gynecol Oncol. 2015;136(1):18-24 https://www.ncbi.nlm.nih.gov/pubmed/?term=25281492
  • 172. Beckmann MW, Juhasz-Bösz I, Denschlag D, Gaß P, Dimpfl T, Harter P, Mallmann P, Renner SP, Rimbach S, Runnebaum I, Untch M, Brucker SY, Wallwiener D. Surgical Methods for the treatment of uterine fibroids – Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGG. Geburtsh Frauenheilk 2015; 2: 148-164 https://www.ncbi.nlm.nih.gov/pubmed/?term=25797958
  • 173. Powles T, Bracarda S, Chen M, Norry E, Compton N, Heise M, Hutson T, Harter P, Carpenter C, Pandite L, Kaplowitz N.
  • Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients.
  • Eur J Cancer. 2015. pii: S0959-8049(15)00286-5. doi: 10.1016/j.ejca.2015.03.019.
  • 174. Hollestelle A, van der Baan FH, Berchuck A,…,Harter P, et al.
  • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2015 May 2. pii: S0090-8258(15)00863-X. doi: 10.1016/j.ygyno.2015.04.034.
  • https://www.ncbi.nlm.nih.gov/pubmed/25940428
  • 175. Baker H, Bandera EV, Bean Y, , Harter P, Heitz F, du Bois, et al. Genome-wide significant risk associations for mucinous ovarian carcinoma. Nat Genet. 2015 Aug;47(8):888-97.
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520768/
  • 176. Lawrenson K, Li Q, Kar S, du Bois, A,…,Harter P, et al.
  • Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nat Commun; 6:8234, 2015 https://www.ncbi.nlm.nih.gov/pubmed/?term=26391404
  • 177. Harter P, Ataseven B, Heitz F, du Bois A,Seltene Tumoren: mesenchymale Tumoren des Uterus. Frauenheilkunde, up2date5, 2015, 325-333
  • 178. Jim HS, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, …, Heitz F, Harter P, du Bois A et al. Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC), J Genet Genome Res, 2(2). pii: 017, 2015
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722961/pdf/nihms729988.pdf
  • 179. Xu CF, Johnson T, Wang X, Carpenter C, …., du Bois A et al.,
  • HLA-B 57:01 confers susceptibility to Pazopanib associated liver injury in patients with cancer; J Clin Oncol, 22(6):1371, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=26546620
  • 180. Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S, Sehouli J. Kommission Ovar of the AGO. Statement by the Kommission Ovar of the AGO : The new FIGO and WHO classifications of Ovarian, Fallopian Tube and Primary peritoneal cancer. Geburtshilfe Frauenheilkd. 2015 Oct ; 75(10) :1021-1027 https://www.ncbi.nlm.nih.gov/pubmed/?term=26556905
  • 181. Ataseven B, Kümmel S, Weikel W, Heitz F, Holtschmidt J, Lorenz-Salehi F, Kümmel A, Traut A, Blohmer J, Harter P, du Bois A. Additional prognostic value of lymph node ratio over pN staging in different breast cancer subtypes based on the results of 1,656 patients. Arch Gynecol Obstet 2015 May;291(5):1153-66 https://www.ncbi.nlm.nih.gov/pubmed/?term=25367604
  • 182. Chornokur G, Lin HY, Tyrer JP, ,Harter P, et al. Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS One. 2015;10(6):e0128106.
  • 183. Denschlag D, Thiel FC, Ackermann S, Harter P, et al.
  • Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 15/074, August 2015). Geburtsh Frauenheilk 2015; 75: 1028-1042
  • 184. Lawrenson K, Iversen ES, Tyrer J,…,Harter P, et al. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. Carcinogenesis. 2015; 6(11):1341-53 https://www.ncbi.nlm.nih.gov/pubmed/?term=26424751
  • 185. Amankwah EK, Lin HY, Tyrer JP,…, Harter P, et al.
  • Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genet Epidemiol. 2015; 39: 689-97 https://www.ncbi.nlm.nih.gov/pubmed/?term=26399219
  • 186. Coetzee SG, Shen HC, Hazelett DJ,….Heitz F, Harter P, du Bois A et al.
  • Cell-type specific enrichment of risk associated regulatory elements at ovarian cancer susceptibility loci. Hum Mol Genet 2015;24:3595-607
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010513/
  • 187. Heil J, Kümmel S, Schaefgen B, Paepke S, Thomssen C, Rauch G, Ataseven B, Grosse R, Dreesmann V, Kuhn T, Loibl S, Blohmer JU, von Minckwitz G.
  • Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. Br J Cancer, 2016;113: 1565-70. https://www.ncbi.nlm.nih.gov/pubmed/?term=26554654
  • 188. Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching PA, Pfitzner BM, Gerber B, Gade S, Darb-Esfahani S, Sinn BV, Huober J, Engels K, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Muller V, Rack B, Schem C, von Minckwitz G.
  • Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. Ann Oncol 2015;26: 95-100.
  • 189. Jackisch C, Muller V, Dall P, Neumeister R, Park-Simon TW, Ruf-Dordel-mann A, Seiler S, Tesch H, Ataseven B. Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers. Geburtshilfe Frauenheilkd l2015;75: 566-573. https://www.ncbi.nlm.nih.gov/pubmed/?term=26166837
  • 190. Ataseven B, Lederer B, Blohmer JU, Denkert C, Gerber B, Heil J, Kuhn T, Kummel S, Rezai M, Loibl S, von Minckwitz G. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6.134 breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol, 2015;22: 1118-27.
  • Publikationen in 2015: 57
  • 2016
  • 191. Lee AW, Templeman C, Stram DA, … du Bois A et al, Evidence of a genetic link between endometriosis and ovarian cancer, Fertil Steril, 105(1):35-43, 2016
  • https://www.ncbi.nlm.nih.gov/pubmed/26477498
  • 192. Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, … du Bois A, .., et al. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer, Gynecol Oncol, 141(2):386-401, 2016
  • https://www.ncbi.nlm.nih.gov/pubmed/25940428
  • 193. Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F. Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8). Gynecol Oncol, 2016, pii:S0090-8258(15)30229-8.doi :10.1016/j.ygyno. 015.12.025
  • https://www.ncbi.nlm.nih.gov/pubmed/26731724
  • 194. du Bois A, Kristensen G, Ray-Coquard I,…, Harter P et al,On behalf of the AGO Study Group led Gynecologic Cancer Intergroup (GCIG)/ European Network of Gynaecologic Oncology Trial Groups (ENGOT) Intergroup Consortium: Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Onc, 17(1):78-89, 2016
  • https://www.ncbi.nlm.nih.gov/pubmed/26731724
  • 195. Xu CF, Johnson T, Wang X, Carpenter C, …, du Bois A, et al. HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients With Cancer, Clin Cancer, 22(6): 1371, 2016
  • https://www.ncbi.nlm.nih.gov/pubmed/26546620
  • 196. Grabowski J, Harter P, Heitz F, Pujade-Lauraine E, Reuss A, Kristensen G, Ray-Coquard I, Heitz J, Traut A, Pfisterer J, du Bois A. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group Metadatabase, Gynecol Oncol, 140(3): 457-62, 2016
  • https://www.ncbi.nlm.nih.gov/pubmed/26807488
  • 197. Heitz F, Harter P, Alesina P, Walz M, …, du Bois A. Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery, Gynecol Oncol, 2016, 141:264-270
  • https://www.ncbi.nlm.nih.gov/pubmed/26975900
  • 198. Prader S, Harter P, Grimm C, Traut A, Waltering KU, Alesina PF, Heikaus S, Ataseven B, Heitz F, Schneider S, du Bois A. Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer, Gynecol Oncol. 2016; 141:271-275 https://www.ncbi.nlm.nih.gov/pubmed/?term=26972337
  • 199. Harter P, du Bois A, Mahner S, Pfisterer J, Ortmann O, Marth C, Fink D, Hilpert F, Wagner U, Sehouli J. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperito-neal Chemotherapy (HIPEC) in Ovarian Cancer, Geburtshilfe Frauenheilkd, 76(2): 147-149, 2016
  • 200. French JD, Johnatty SE, Lu Y, Beesley J, …, du Bois A, Harter P et al. Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer, Oncotarget, 7(6): 6353-68, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=26840454
  • 201. Ataseven B, Grimm C, Harter P, Heitz F, Traut A, Prader S, du Bois A. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV, Gynecol Oncol, 140(2): 215-20, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=26691222
  • 202. Davisa SJ, Sheppard KE, Anglesiof MS, George J, … du Bois A et al. Enhanced GAB2 expression is associated with improved survival in high-grade serous ovarian cancer and sensitivity to PI3K inhibition, Mol Cancer Ther, 14(6): 1495-503, 2016
  • 203. Gonzalez-Martin A, Pautier P, Mahner S, Rau J, Colombo N, Ottevanger P, del Campo JM, Selle F, du Bois A, Gadducci A, García Y, Berton-Rigaud D, Marmé F, Ortega E, Martin N, Bastiere-Truchot L, Kiermaier A, Kurzeder C, Pertuzumab plus chemotherapy for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial, Int J Gynecol Cancer; 26(5): 898-905, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27206218
  • 204. Mahner S, Trillsch F, Chi D, Harter P, Pfisterer J, Hilpert F, Burges A, Weissenbacher T, du Bois A. Neoadjuvant chemotherapy in ovarian cancer revisited, Ann Oncol, 27(S1):i30-i32, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27141067
  • 205. du Bois A, Trillsch F, Mahner S, Heitz F, Harter P. Management of borderline ovarian tumors (BOT), Ann Oncol, 27, (S1):i20-i22, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27141065
  • 206. Ataseven B, Chiva LM, Harter P, Gonzalez-Martin A, du Bois A. FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. Int J Gynecol Cancer; 142(3):597-607, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27335253
  • 207. Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A. Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE), J Clin Oncol, 34(21):2516-25, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27269942
  • 208. Ataseven B, Harter P, Grimm C, Heitz F, Heikaus S, Traut A, Kahl A, Kurzeder C, Prader S, du Bois A. The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified? Gynecol Oncol, 142(2):243-7, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27208538
  • 209. Harter P, Sehouli J, Reuss A, Baumann K, Hanker L, Kimmig R, Schröder W, Burges A, Gropp-Meier M, Kurzeder C, Mahner S, Canzler U, Lück HJ, Meier W, Fehm T, du Bois A. Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the AGO Study Group (AGO-GYN 7), Int J Gynecol Cancer, 26(9):1636-1641, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27654266
  • 210. Harter P, Johnson T, Berton-Rigaud D, Park SY, Friedlander M, du Bois A, BRCA 1/2 mutations associated with progression-free survival in Ovarian Cancer patients in the AGO OVAR 16 study. Gynecol Oncol, 140(3): 443-449, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=26740259
  • 211. Ataseven B, du Bois A, Harter P, Prader S, Grimm C, Kurzeder C, Schneider S, Heikaus S, Kahl A, Traut A, Heitz F. Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer, Int J Gynecol Cancer, 26(9):1594-1600, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27654263
  • 212. Kommoss S, Gilks CB, du Bois A, Kommoss F. Ovarian carcinoma diagnosis: the clinical impact of 15 years of change, Br J Cancer. 115(8):993-999, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27632374
  • 213. Southey M, Goldgar D, Winqvist R, Pylkäs K, Couch F, Tischkowitz M, …, du Bois A, et al. ATM, PALB2 and CHEK2 rare variants and cancer risk: data from COGS, J Med Genet, 53(12):800-811, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27595995
  • 214. Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B, Harter P, Lundvall L, Marth C, Morice P, Rafii A, Ray-Coquard I, Rockall A, Sessa C, van der Zee A, Vergote I, du Bois A. European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery.Int J Gynecol Cancer; 26(7): 1354-63, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27648648
  • 215. Klar M, Hasenburg A, Hasanov M, Hilpert F, Meier W, Pfisterer J, Pujade-Lauraine E, Herrstedt J, Reuss A, du Bois A. Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO, Eur J Cancer; 66: 114-24, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27561452
  • 216. Ataseven B, Grimm C, Harter P, Heikaus S, Heitz F, Traut A, Prader S, Kahl A, Schneider S, Kurzeder C, du Bois A. Prognostic Impact of Port-Site Metastasis After Diagnostic Laparoscopy for Epithelial Ovarian Cancer, Ann Surg Oncol, 23:834-840,2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27406097
  • 217. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, …, du Bois A et al. Niraparib Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer, New Engl J Med. 375(22):2154-2164, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27717299
  • 218. du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S et al. Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905-1914], Eur J Cancer;65:192-193, 2016
  • 219. Hampras S, Sucheston-Campbell, Cannioto R, , … du Bois, Harter P et al, Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer, Oncotarget, doi: 10.18632/oncotarget 7(43):69097-69110, 2016
  • 220. Felber S, Voiß P, Paul A, Dobos G, du Bois A. Komplementärmedizinische Therapieansätze in der gynäkologischen Onko-logie – Nutzen und Grenzen, Geburtsh Frauenh; 76, 10.1055/s-0042-109734, 2016
  • 221. Lheureux S, Karakasis K, Harter P, Scott C, Bacon M, Bryce J, Le Fur N, Pujade-Lauraine E, Oza AM. Germline BRCA1/2 Testing Practices in Ovarian Cancer: Current State and Opportunities for New Directions. Gynecol Oncol 2016; 140(1):90-94 https://www.ncbi.nlm.nih.gov/pubmed/?term=26475959
  • 222. Meinhold-Heerlein, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S, Sehouli J for the Kommission Ovar of the AGO. Statement by the Kommission Ovar of the AGO: The new WHO Classification of Ovarian, Fallopian Tube and Primary Peritoneal Cancer and its clinical implications. Arch Gynecol Obstet. 2016;293(4):695-700.
  • 223. Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Parry D, Grinsted L, Ledermann JA. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer. 2016;122(12):1844-52 https://www.ncbi.nlm.nih.gov/pubmed/?term=27062051
  • 224. Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol, 17(11):1579-1589, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27617661
  • 225. Southey MC, Goldgar DE, Winqvist R,…, Harter P, et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 53(12):800-811, 2016
  • 226. Sehouli J, Chekerov R, Rheinthaller A, Richter R, Gonzalez-Martin A, Harter P, et al. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Ann Oncol, 27(12):2236-2241, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27789470
  • 227. Ledermann JA, Harter P, Gourley C, et al. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer. 2016 Nov 8. doi: 10.1038/bjc.2016.348. https://www.ncbi.nlm.nih.gov/pubmed/?term=27824811
  • 228. Woelber L, Griebel LF, Eulenburg C,…,Harter P, et al. Role of tumour-free margin distance for loco-regional control in vulvar cancer – s subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study. Eur J Cancer 2016; 69: 180-188
  • 229. Ataseven B, von Minckwitz G. The Impact of Neoadjuvant Treatment on Surgical Options and Outcomes. Ann Surg Oncol, 2016; 23: 3093-3099 https://www.ncbi.nlm.nih.gov/pubmed/?term=27364505
  • 230. Reinisch M, Ataseven B, Kummel S. Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature. Breast Care (Basel), 2016; 11: 13-20 https://www.ncbi.nlm.nih.gov/pubmed/?term=27051390
  • 231. Schwentner L, Helms G, Nekljudova V, Ataseven B, Bauerfeind I, Ditsch N, Fehm T, Fleige B, Hauschild M, Heil J, Kummel S, Lebeau A, Schmatloch S, Schrenk P, Staebler A, Loibl S, Untch M, Von Minckwitz G, Liedtke C, Kuhn T. Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial. Breast, 2016;31: 202-207 https://www.ncbi.nlm.nih.gov/pubmed/?term=27889596
  • 232. Liu JF, Ray-Coquard I, Selle F, Poveda AM, Cibula D, Hirte H, Hilpert F, Raspagliesi F, Gladieff L, Harter P, Siena S, Del Campo JM, Tabah-Fisch I, Pearlberg J, Moyo V, Riahi K, Nering R, Kubasek W, Adiwijaya B, Czibere A, Naumann RW, Coleman RL, Vergote I, MacBeath G, Pujade-Lauraine E. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. J Clin Oncol. 2016 Dec 20;34(36):4345-4353. https://www.ncbi.nlm.nih.gov/pubmed/?term=27998236
  • 233. Heitz F, Harter P, Ataseven B, du Bois A. Response to the letter of Fagotti et al. regarding the manuscript: "Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery". Gynecol Oncol Rep. 2016 Nov 11;18:55-56.
  • 234. Pulford DJ, Harter P, Floquet A, Barrett C, …, du Bois A. Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study, BMC Med Ethics; 17(1): 63, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27769273
  • 235. du Bois A. Making the most of every option in the treatment of ovarian cancer.Expert Rev Anticancer Ther. 2016 Nov;16(sup1):1, doi:10.1080/14737140. 2016.1243476, 2016
  • 236. González-Martín A, du Bois A. Factors to consider and questions to ask in the management of recurrent ovarian cancer: a focus on the role of trabectedin + pegylated liposomal doxorubicin, Expert Rev Anticancer Ther, 16(sup1): 3-10, 2016 https://www.ncbi.nlm.nih.gov/pubmed/?term=27797624
  • 237. Sporkmann M, Heitz F, Harter P. Therapie und Prognosefaktoren uteriner Sarkome - Was ist neu? Thieme, Geburtshilfe und Frauenheilkunde 2016; 76 (11): 1126-1131
  • Publikationen in 2016: 47
  • 2017
  • 238. Fotopoulou C, Sehouli J, Aletti G, Harter P, Mahner S, Querleu D, Chiva L, Gabra H, Colombo N, du Bois A. Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective. J Clin Oncol. 35(6):587-590, 2017 https://www.ncbi.nlm.nih.gov/pubmed/?term=28068169
  • 239. Chiva L, Querleu D, Cibula D, du Bois A. European Surgical Education and Training in Gynecologic Oncology. The impact of an Accredited Fellowship, , Int J Gynecol Cancer.; 27(4):819-825 2017 https://www.ncbi.nlm.nih.gov/pubmed/?term=28410284
  • 240. Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Heitz, F…, du Bois A, …, Harter P, .., et al. No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival, Cancer Epidemiol Biomarkers Prev. 26(3):420-424, 2017 https://www.ncbi.nlm.nih.gov/pubmed/?term=27677730
  • 241. Heitz F, Hengsbach A, Harter P, Traut A, Ataseven B, Schneider S, Prader S, Kurzeder C, Sporkmann M, du Bois A. Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer. Gynecol Oncol. 144(1):181-186, 2017 https://www.ncbi.nlm.nih.gov/pubmed/?term=27863705
  • 242. Moebus V, von Minckwitz G, Jackisch C, Lueck H-J, Schneeweiss A, …, du Bois A et al. German Adjuvant Intergroup Node-positive Study (GAIN): A Phase III Trial to Compare Two Dose-Dense Regimens (iddETC vs. EC-TX) in High-Risk Early Breast Cancer Patients. Ann Oncol, doi: 10.1093/annonc/mdx203, 2017
  • https://www.ncbi.nlm.nih.gov/pubmed/28459941
  • 243. Kommoss S, Winterhoff B, Oberg AL, … du Bois A et al, Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtype, Clin Cancer Res, 23(14):3794-3801, 2017 https://www.ncbi.nlm.nih.gov/pubmed/?term=28159814
  • 244. Glubb D, Johnatty S, Quinn M, O’Mara T,TyrerJ, …, du Bois A et al. Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget, doi: 10.18632/oncotarget.18501, 2017 https://www.ncbi.nlm.nih.gov/pubmed/?term=29029385
  • 245. Harter P, Reuss A, Sehouli J, Chiva L, du Bois A. Brief report about the role of hyperthermic intraperitoneal chemotherapy in a prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et al. Int J Gyn Cancer, 27(2):246-247, 2017
  • 246. McGee J, Bookman M, Harter P, Marth C, …..et al. 5th Ovarian Cancer Consensus Conferenz: Individualized therapy and patient factors. Ann Oncology, 28(4):702-710, 2017 https://www.ncbi.nlm.nih.gov/pubmed/?term=28119296
  • 247. Sehouli J, Mahner S, Harter P, Hilpert F, du Bois A., et al. Aktuelle Änderungen der S3-Leitlinie Maligne Ovarialtumoren (Version 2.0 – Oktober 2016) Klinikarzt, 46: 206-211, 2017
  • 248. Marth C, Vergote I,……, Kurzeder, C, Colombo N….et al. ENGOT-ov-6/TRINOVA-2 : Randomised double, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer, 70, 70:111-121, 2017
  • 249. Klapdor R, Hillemanns P, Wölber L, Jückstock J, Hilpert F, de Gregorio N, Iborra S, Sehouli J,..., Harter P, Wimberger P, ....Schmalfeldt B,...., Jäger M, Mahner S. Outcome After Sentinel Lymph Node Dissection in Vulva Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study. Ann Surg Oncol.,2017, 24():1314-1321 https://www.ncbi.nlm.nih.gov/pubmed/?term=27896515
  • 250. Harbeck N, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, .., du Bois A, Lück HJ, Harter P, Göhler T, Augustin D, Harnett P, Lipp R, Beckmann M, Al-Batran SE on behalf of the PELICAN investigators. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: Results of the PELICAN study. Breast Cancer Res Treat, 161(1):63-72, 2017 https://www.ncbi.nlm.nih.gov/pubmed/?term=27798749
  • 251. Sucheston-Campbell LE, Cannioto R, Clay Al,…, Harter P, et al No evidence that genetic variation in the myeloid-derived suppressor cell pathweay influences ovarian cancer survival. Cancer Epi Biomarkers Prev, 2017, 26(3):420-424 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500198/
  • 252. Harter P, Reuss A, Sehouli J, Chiva L, du Bois A.
  • Brief report about the role of hyperthermic intraperitoneal chemotherapy n prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et al. Int J Gynecol Cancer, 2017 Feb; 27(2):246-247
  • 253. Schneider S, Heikaus S, Harter P, Heitz F, Grimm C, Ataseven B, Prader S, Kurzeder C, Ebel T, Traut A, du Bois A. Serous tubal intraepitelial carcinoma associated with extraovarian metastases, Int J Gyn Cancer, 2017, 27(3):444-451 https://www.ncbi.nlm.nih.gov/pubmed/?term=28187099
  • 254. Chekerov R, Harter P, Fuxius S, et al. Preference of elderly patients to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian caner: final results of prospective multicenter trail. Gyn Oncol Res Pract., 4:6. doi: 10.1186/s40661-017-0040-2, 2017 (eCollection)
  • 255. Pujade-Lauraine E, Ledermann J, Selle F, ....., Harter P,...., SOLO2/ENGOT-Ov21 investigators.
  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomized, placebo-controlled, phase 3 trial. The Lancet Onc, dx.doi.org/10.1016/S1470-2045(19)30469-2, 2017
  • 256. Minig L, Heitz F, Cibula D, Bakkum-Gamez JN, Germanova A, ….Harter P, du Bois A, Fotopolou C, et al, Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study, Ann Surg Oncol. 24(9):2720-2726, 2017 https://www.ncbi.nlm.nih.gov/pubmed/?term=28608122
  • 257. Grimm C, Harter P, Alesina PF, Prader S, Schneider S, Ataseven B, Meier B, Brunk-horst V, Hinrichs J, Kurzeder C, Heitz F, Kahl A, Traut A, Groeben HT, Walz M, du Bois A.The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery. Gynecol Oncol. 2017 Jun 10. pii: S0090-8258(17)30936-8. doi: 10.1016/j.ygyno.2017.06.007. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/?term=28610745
  • 258. Kahl A, du Bois A, Harter P, Prader S, Schneider S, Heitz F, Traut A, Alesina PF, Meier B, Walz M, Brueckner A, Groeben HT, Violeta B, Heikaus S, Ataseven B. The prognostic value of the Age-Adjusted Charlson-Comorbidity-Index (ACCI) on short and long term outcome in patients with advanced primary epithelial ovarian cancer. Ann Surg Oncol 2017
  • https://www.ncbi.nlm.nih.gov/pubmed/?term=28871563
  • 259. Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, du Bois A, Vergote I, Reuss A, Bacon M, Friedlander M, Rincon D, Joly F, Chang SJ, Ferrero AM, Edmondson RJ, Wimberger P, Maenpaa J, Gaffney D, Zhang R, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference, Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease Ann Oncol. 28(4): 727-732, 2017 https://www.ncbi.nlm.nih.gov/pubmed/?term=27993805
  • 260. Kommoss S, Kommoss F, Diebold J, Lax S, Schmidt D, Staebler A, du Bois A, Pfisterer J. Better resource utilisation and quality of care for ovarian cancer patients using internet-based pathology review, Brit J Cancer. 116(3):287-292, 2017 https://www.ncbi.nlm.nih.gov/pubmed/?term=28006819
  • 261. Harter P. Comment: A new standard of care or just another option for patients with relapsed ovarian cancer. Lancet Oncol 2017;18(6):701-702 https://www.ncbi.nlm.nih.gov/pubmed/?term=28438475
  • 262. Möbus V. … du Bois A…. et al.
  • Ten-year Results of Intense Dose-dense chemotherapy show superior survival compared to a conventional schedule in High-risk Primary Breast Cancer: Final results of AGO Phase III iddEPC trial.
  • https://www.ncbi.nlm.nih.gov/pubmed/29069370
  • 264. Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F,… du Bois A et al.
  • Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive
  • ovarian cancer patients (AGO-TR-1).
  • PLoS One. 2017 Oct 20;12(10):e0186043. doi: 10.1371/journal.pone.0186043. eCollection
  • 2017.
  • journals.plos.org/plosone/article